Thromboembolic Disease and Antithrombotic Therapy

Dear Colleagues,

Venous thromboembolism is a common disorder affecting up to 1 in 12 individuals in their lifetime, with substantial healthcare and socioeconomic costs due to its recurrence and complications. The introduction of direct oral anticoagulant in the last decade marked a paradigm shift in the management of VTE, although there remains significant disease burden represented by chronic complications such as post thrombotic syndrome and chronic thromboembolic pulmonary hypertension, risk of recurrent thrombosis, bleeding risk associated with anticoagulation and substantial mortality. Despite improved acute VTE management, the management of chronic complications remains inadequate. More recently, Factor XI and XII have emerged as potential new targets for novel anticoagulants.

The next challenge in thrombosis management is the development of effective risk stratification methods using novel biomarkers to encompass the multifactorial contributors to thrombosis, including the various components of Virchow’s triad and taking into account epigenetic mechanisms in modulating VTE. Much refinement is still required to ensure the equilibrium between thrombotic and bleeding risk is carefully maintained. These biomarkers, when identified, will allow the transition of traditional thrombosis care into personalised medicine, and facilitate the development of specific targeted therapies for this heterogenous disease. 

This Special Issue aims to bring together a body of literature which discusses the latest research in thromboembolic disease and antithrombotic therapy as we move towards personalised VTE therapy.

Dr. Prahlad Ho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.